Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects.

Moriau, Maurice;Crasborn, L.;Lavenne-Pardonge, E.;von Frenckell, R.;Col-Debeys, C.
(1993) Arzneimittel-Forschung — Vol. 43, n° 2, p. 110-118 (1993)

Files

No attached file found for this publication.

Details

Authors
  • Moriau, MauriceUCLouvain
    Author
  • Crasborn, L.UCLouvain
    Author
  • Lavenne-Pardonge, E.UCLouvain
    Author
  • von Frenckell, R.UCLouvain
    Author
  • Col-Debeys, C.UCLouvain
    Author
Abstract
The random administration of four different single oral doses of piracetam (Nootropil, CAS 7491-74-9)--1.6 g, 3.2 g, 4.8 g and 9.6 g--at fixed intervals of 2 weeks to 5 healthy subjects has confirmed and explicited its platelet anti-aggregant and rheological properties after doses of 4.8 g and 9.6 g. The effect on platelet aggregation occurs through inhibition of thromboxane synthetase or anti-thromboxane A2 activity together with a reduction in the plasma level of von Willebrand's factor (F.VIIIR:vW). The rheological effect is related to the action of piracetam on cell membrane deformability (red cells, white cells and platelets) and to its simultaneous effect in reducing by 30-40% plasma levels of fibrinogen and von Willebrand's factor. In addition, it exerts a direct stimulant effect on prostacyclin synthesis in healthy endothelium. These effects are greatest between 1 and 4 h after dosage, and then diminish progressively to disappear between 8 and 12 h after administration. This explains the need to divide the total daily dose into 3 intakes at 8-hourly intervals. This study confirms the presence of four sites of action of piracetam: the vessel wall, platelets, plasma and cell membranes (RBC, WBC), which provide the basis for the potentially important antithrombotic activity of piracetam.
Affiliations

Citations

Moriau, M., Crasborn, L., Lavenne-Pardonge, E., von Frenckell, R., & Col-Debeys, C. (1993). Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittel-Forschung, 43(2), 110-118. https://hdl.handle.net/2078.5/50107 (Original work published 1993)